Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.
Advertisement
Follow the links below to read about each product:
Articles in this issue
over 1 year ago
Pharmaceutical Executive: July/August 2024 Issue (PDF)over 1 year ago
An AI Pulse Checkover 1 year ago
A Promising Option: Exxuaover 1 year ago
Opening the Door: Omvohover 1 year ago
'Marked’ for Stardom?: Truqapover 1 year ago
Branching Off: Wegovyover 1 year ago
A Formidable First: Winrevairover 1 year ago
The Future of Launch Excellence is Generative AIover 1 year ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'over 1 year ago
Big Bets, Bold StepsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
2
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
3
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
4
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
5